Serological SARS‐CoV‐2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID‐19 vaccine in haematological and oncological patients

Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia

(2021) Yair Herishanu et al.   BLOOD

Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia

(2021) Stefanie Kreutmair et al.   IMMUNITY

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

(2021) Fulvia Pimpinelli et al.   Journal of Hematology & Oncology

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors

(2021) Barliz Waissengrin et al.   LANCET ONCOLOGY

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

(2021) Leticia Monin et al.   LANCET ONCOLOGY

Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma

(2021) Sarah Bird et al.   Lancet Haematology

COVID-19 Vaccines in Patients With Cancer—A Welcome Addition, but There Is Need for Optimization

(2021) Eleni Korompoki et al.   JAMA Oncology

Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients

(2021) Abi Vijenthira et al.   Blood Advances

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines

(2020) Christopher Pleyer et al.   BLOOD

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia

(2020) Valentina Griggio et al.   Frontiers in Immunology

The how’s and what’s of vaccine reactogenicity

(2019) Caroline Hervé et al.   npj Vaccines

Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group

(2018) Tobias Svensson et al.   VACCINE

Seasonal influenza vaccine in immunocompromised persons

(2018) Mohammad Bosaeed et al.   Human Vaccines & Immunotherapeutics

Influenza vaccination for immunocompromised patients: summary of a systematic review and meta-analysis

(2013) Charles R Beck et al.   Influenza and Other Respiratory Viruses

A possible relationship of natural killer T cells with humoral immune response to 23-valent pneumococcal polysaccharide vaccine in clinical settings

(2012) Tomomitsu Miyasaka et al.   VACCINE